Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

by El Hajbi, Farid , Bridgewater, John , Hsu, Chih-Hung , Wyrwicz, Lucjan , Xynos, Ioannis , Lei, Ming , Yang, Wen-Chi , Kim, Hye R , Liu, Xuan , Liu, Tianshu , Doki, Yuichiro , Adenis, Antoine , Ueno, Masaki , Ogata, Takashi , Kitagawa, Yuko , Kawakami, Hisato , Xu, Jianming , Ajani, Jaffer A , Makino, Tomoki , Holtved, Eva , Di Bartolomeo, Maria , Chau, Ian , Kondo, Kaoru , Ostoich, Sandra A , Gricar, Joseph , Mansoor, Wasat , Braghiroli, Maria I , Motoyama, Satoru , Patel, Apurva , Kato, Ken

in Adult / Aged / Aged, 80 and over / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Apoptosis / B7-H1 Antigen - antagonists & inhibitors / Cancer therapies / Carcinoma, Squamous Cell - drug therapy / Carcinoma, Squamous Cell - mortality / Cell death / Chemotherapy / Combination therapy / Confidence intervals / Esophageal cancer / Esophageal Neoplasms - drug therapy / Esophageal Neoplasms - mortality / Esophagus / Female / Gastroenterology / Gastrointestinal Tract Cancer / Hematology / Humans / Immune Checkpoint Inhibitors - administration & dosage / Immune Checkpoint Inhibitors - adverse effects / Immunotherapy / Ipilimumab - administration & dosage / Ipilimumab - adverse effects / Male / Metastases / Metastasis / Middle Aged / Monoclonal antibodies / Nivolumab - administration & dosage / Nivolumab - adverse effects / Oncology / Patients / PD-L1 protein / Progression-Free Survival / Squamous cell carcinoma / Survival Analysis / Targeted cancer therapy / Treatments in Oncology / Tumors

2022

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

2022

Confirm

Do you wish to request the book?

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

2022

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

El Hajbi, Farid,

Bridgewater, John,

Hsu, Chih-Hung,

Wyrwicz, Lucjan,

Xynos, Ioannis,

Lei, Ming,

Yang, Wen-Chi,

Kim, Hye R,

Liu, Xuan,

Liu, Tianshu,

Doki, Yuichiro,

Adenis, Antoine,

Ueno, Masaki,

Ogata, Takashi,

Kitagawa, Yuko,

Kawakami, Hisato,

Xu, Jianming,

Ajani, Jaffer A,

Makino, Tomoki,

Holtved, Eva,

Di Bartolomeo, Maria,

Chau, Ian,

Kondo, Kaoru,

Ostoich, Sandra A,

Gricar, Joseph,

Mansoor, Wasat,

Braghiroli, Maria I,

Motoyama, Satoru,

Patel, Apurva,

Kato, Ken

2022

Overview

Previously untreated patients with advanced esophageal cancer were randomly assigned to receive chemotherapy alone, chemotherapy plus nivolumab, or nivolumab plus ipilimumab. Among patients with tumor-cell PD-L1 expression of 1% or greater, the two nivolumab regimens resulted in longer overall survival than chemotherapy. The side-effect profile was consistent with past reports on these agents.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adult

/ Aged

/ Aged, 80 and over

/ Antineoplastic Combined Chemotherapy Protocols - adverse effects

/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use

/ Apoptosis

/ B7-H1 Antigen - antagonists & inhibitors